Moleculin Biotech Files 8-K on Security Holder Vote
Ticker: MBRX · Form: 8-K · Filed: Oct 16, 2025 · CIK: 1659617
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, disclosure
Related Tickers: MBRX
TL;DR
Moleculin Biotech (MBRX) is having a shareholder vote.
AI Summary
Moleculin Biotech, Inc. filed an 8-K on October 16, 2025, reporting on the submission of matters to a vote of security holders. The filing details the company's corporate structure, including its state of incorporation (Delaware) and fiscal year end (December 31).
Why It Matters
This filing indicates that Moleculin Biotech is engaging its security holders in a decision-making process, which could impact the company's future direction or governance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not indicating any immediate financial distress or significant operational change.
Key Numbers
- 001-37758 — SEC File Number (Identifies the company's filing with the SEC.)
- 47-4671997 — EIN (Employer Identification Number for Moleculin Biotech, Inc.)
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- October 16, 2025 (date) — Date of Report
FAQ
What specific matters are being submitted for a vote of security holders?
The provided text does not specify the exact matters to be voted on, only that the filing pertains to the 'Submission of Matters to a Vote of Security Holders'.
When was the earliest event reported in this 8-K filing?
The earliest event reported is October 16, 2025, which is also the date of the report.
What is Moleculin Biotech, Inc.'s principal executive office address?
The principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, TX 77007.
What is Moleculin Biotech, Inc.'s telephone number?
The company's telephone number is (713) 300-5160.
What is the Standard Industrial Classification (SIC) code for Moleculin Biotech, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 703 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2025-10-16 11:16:08
Filing Documents
- mbrx20251013_8k.htm (8-K) — 28KB
- logobig.jpg (GRAPHIC) — 19KB
- 0001437749-25-031123.txt ( ) — 210KB
- mbrx-20251016.xsd (EX-101.SCH) — 3KB
- mbrx-20251016_def.xml (EX-101.DEF) — 12KB
- mbrx-20251016_lab.xml (EX-101.LAB) — 15KB
- mbrx-20251016_pre.xml (EX-101.PRE) — 12KB
- mbrx20251013_8k_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On October 16, 2025, the Company held a Special Meeting of Stockholders (the "Special Meeting"). As of August 28, 2025, the record date for the Special Meeting, there were 36,739,360 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Special Meeting, of which 14,737,799 shares were present in person or represented by proxy, which constituted a quorum. The holders of shares of our common stock are entitled to one vote for each share held. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Special Meeting. Each of these proposals is described in greater detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 15, 2025 (the "Proxy Statement"). Proposal 1. Approve the Nasdaq Proposal for Certain Warrants Issued on August 28, 2025 - The Company's stockholders approved the issuance of up to 64,864,864 shares of Company common stock upon the exercise of certain warrants issued on August 28, 2025, by the following vote:. Votes For Votes Against Abstain Broker Non-Votes 4,937,555 1,479,087 142,257 8,178,900 Proposal 2. Approve an Amendment to Change the Company ' s Name from Moleculin Biotech, Inc. to Moleculin Inc. - The Company's stockholders did not approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to change the Company's name from Moleculin Biotech, Inc. to Moleculin Inc. (as such vote required a majority of the outstanding shares on the record date to vote "For" which did not occur) by the following vote: Votes For Votes Against Abstain Broker Non-Votes 11,258,199 843,364 2,636,236 0 Proposal 3. Approve an Adjournment - The Company's stockholders approved an adjournment, if necessary, to solicit additional proxies if there are not sufficient